Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer

Based on our previous phase II clinical trial of anti-programmed death-1 (PD-1) antibody nivolumab for platinum-resistant ovarian cancer (n = 19, UMIN000005714), we aimed to identify the biomarkers predictive of response. Tumor gene expression was evaluated by proliferative, mesenchymal, differentia...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Murakami, Ryusuke, Hamanishi, Junzo, Brown, J. B., Abiko, Kaoru, Yamanoi, Koji, Taki, Mana, Hosoe, Yuko, Yamaguchi, Ken, Baba, Tsukasa, Matsumura, Noriomi, Konishi, Ikuo, Mandai, Masaki
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8169687/
https://ncbi.nlm.nih.gov/pubmed/34075161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-91012-w
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller